Piramal Pharma Faces Financial Challenges Amidst Long-Term Growth Potential and Market Adjustments

Piramal Pharma has recently undergone an evaluation adjustment, reflecting notable shifts in its financial metrics and market position. The company's financial performance for the quarter ending June 2025 has shown a significant decline, with a reported PAT of Rs -102.44 crore, marking a substantial change compared to the previous four-quarter average. This has contributed to a revision in its score, which has shifted from a previously positive standing to a more negative outlook.
On a positive note, the company has reported a PAT of Rs 51.06 crore over the latest six months, indicating a growth rate of 94.76%. Additionally, its operating cash flow has reached a high of Rs 548.77 crore. However, challenges persist, as the operating profit to interest ratio stands at its lowest at 1.24 times, and net sales have also hit a low of Rs 1,933.71 crore.

Despite these hurdles, Piramal Pharma has demonstrated healthy long-term growth potential, with an annual operating profit growth rate of 31.99%. The stock is currently trading at a discount compared to its peers, and it has maintained a return on equity of 0.87%.

For more insights on Piramal Pharma's financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.